Brief: Better Therapeutics Expects Pivotal Trial Of BT-001 In Type 2 Diabetes To Be Fully Enrolled In Q4 2021
09/09/2021 13:09
Sept 9 (Reuters) - Better Therapeutics Inc:
* BETTER THERAPEUTICS - PIVOTAL TRIAL OF BT-001 IN TYPE 2
DIABETES
EXPECTED TO BE FULLY ENROLLED IN Q4 2021, WITH PRIMARY ENDPOINT
READOUT IN Q1 2022
* BETTER THERAPEUTICS - CLINICAL DEVELOPMENT OF BT-002,
BT-003 IN
HYPERTENSION AND HYPERLIPIDEMIA ON TRACK; PIVOTAL STUDIES
EXPECTED TO COMMENCE IN 2022
Source text for Eikon: ID:nBwbTcLg8a
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Better Therapeutics
See all newsU.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
U.S. STOCKS ON THE MOVE-G-III Apparel Group, Tesla, MicroStrategy